IntellAif
Translating Discoveries Into Therapies — Faster and Smarter
We accelerate drug development by improving the translatibility of preclinical models with AI.
Pharmaceutical companies face an enduring challenge: too many promising drug candidates fail in clinical trials due to a lack of efficacy. At IntellAif, we are revolutionizing drug development by ensuring the translatability of preclinical models. We use DeepTech to de-risk preclinical investigation. Our X-Bio™ Research Platform and BioSync™ provide state of the art analytics and confidence scores to your preclinical data.
X-Bio® Research Platform
An advanced research companion and analytical platform designed to accelerate the translation of discoveries into effective therapies.
AI-Powered Insights
Leverage advanced AI algorithms for optimized and drug tailored preclinical model selection and improvement strategies.
Deep Exploration
Deep dive into molecular and pathway level differences for enhanced translatability.
Decision De-risking
Informed go/no-go decisions advised by our trademarked BioSync® score.
Data Integration
Securely connect your data for model finetuning.
Data Privacy
Remote private inference and ISO/IEC 27001 and ISO/IEC 27701 certification ensures robust information security and privacy management.
Database
Our proprietary database is built through strategic collaborations with leading consortia and academic institutions. IntellAif processes this data to ensure it is context-specific and meets our rigorous quality control standards.
“Designed with purpose. Built with care. Bringing clarity to preclinical investigations.
Paving the way to drug development success.”
Get priority on our demonstrations and share with us your use cases.
Your projects are kept highly secure, importing our models to be fine tuned with your data. We do not get access to your data.
Collect all relevant preclinical models and investigations on your dashboard that are relevant to your project and pipeline.
DeepTech built on Multimodal Biological Data
Foundational models trained on multimodal biological data deliver state-of-the-art predictions of clinically relevant insights, grounded in preclinical investigations.
Testimonials
Significant need
There is a significant need here. Better validation of preclinical models is key to clinical translation.
Professor of Genetics
Karolinska Institutet
A new tool required
A new tool is required for me to better predict clinical trial protocols from my preclinical models.
CEO
SME pharma
Scoring is essential
Just the BioSync Score alone would be useful for us as a talking point.
Preclinical scientist
Big Pharma
AI-driven solutions wanted!
Big pharmaceutical companies are shifting away from in-house R&D and instead acquiring AI driven technologies to solve key challenges.
Business leader
Big Pharma
Recent News
Follow our company's journey.
The Rise of Novel Approach Methodologies
How IntellAif is Shaping the Future of Preclinical Drug Development